Evidence map›Paper›PMID 34918187›Full record

ArticleActa neuropathologica2022

DTYMK is essential for genome integrity and neuronal survival.

Jo M Vanoevelen, Jörgen Bierau, Janine C Grashorn, Ellen Lambrichs, Erik-Jan Kamsteeg, Levinus A Bok, Ron A Wevers, Marjo S van der Knaap, Marianna Bugiani, Junmei Hu Frisk and 10 more

Open access · hybridAbstract readCase Reports
In one paragraph

Article in Acta neuropathologica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. The evolving landscape of involvement of DTYMK enzymes in cancer.Medical oncology (Northwood, London, England) · 2023
    Review
  7. Article
  8. Article
  9. Article
  10. Targeting theFrontiers in cellular and infection microbiology · 2022
    Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 7 institutions in 5 countries.

Jo M Vanoevelen *Department of Clinical Genetics, Maastricht University Medical Centre+, 6229 ER, Maastricht, The Netherlands. j.vanoevelen@maastrichtuniversity.nl.ORCID 0000-0003-1830-8858
Jörgen Bierau *Department of Clinical Genetics, Maastricht University Medical Centre+, 6229 ER, Maastricht, The Netherlands.
Janine C GrashornDepartment of Clinical Genetics, Maastricht University Medical Centre+, 6229 ER, Maastricht, The Netherlands.
Ellen LambrichsDepartment of Clinical Genetics, Maastricht University Medical Centre+, 6229 ER, Maastricht, The Netherlands.
Erik-Jan KamsteegDepartment of Human Genetics, Radboud UMC, 6525 GA, Nijmegen, The Netherlands.
Levinus A BokDepartment of Pediatrics, Màxima Medical Center, 5504 DB, Veldhoven, The Netherlands.
Ron A WeversTranslational Metabolic Laboratory, Radboud UMC, 6525 GA, Nijmegen, The Netherlands.
Marjo S van der KnaapDepartment of Child Neurology, VUMC, 1105 AZ, Amsterdam, The Netherlands.
Marianna BugianiDepartment of Neuropathology, VUMC, 1105 AZ, Amsterdam, The Netherlands.
Junmei Hu FriskDepartment of Anatomy, Physiology and Biochemistry, Swedish University of Agricultural Sciences, 75007, Uppsala, Sweden.
Rita ColnaghiGenome Damage and Stability Centre, University of Sussex, Brighton, BN1 9RH, UK.
Mark O'DriscollGenome Damage and Stability Centre, University of Sussex, Brighton, BN1 9RH, UK.
Debby M E I HellebrekersDepartment of Clinical Genetics, Maastricht University Medical Centre+, 6229 ER, Maastricht, The Netherlands.
Richard RodenburgTranslational Metabolic Laboratory, Radboud UMC, 6525 GA, Nijmegen, The Netherlands.
Carlos R FerreiraNational Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
Han G BrunnerDepartment of Clinical Genetics, Maastricht University Medical Centre+, 6229 ER, Maastricht, The Netherlands.
Arthur van den WijngaardDepartment of Clinical Genetics, Maastricht University Medical Centre+, 6229 ER, Maastricht, The Netherlands.
Ghada M H Abdel-SalamDepartment of Clinical Genetics, Human Genetics and Genome Research Division, National Research Centre, Cairo, 12311, Egypt.
Liya WangDepartment of Anatomy, Physiology and Biochemistry, Swedish University of Agricultural Sciences, 75007, Uppsala, Sweden.
Constance T R M StumpelDepartment of Clinical Genetics, Maastricht University Medical Centre+, 6229 ER, Maastricht, The Netherlands. c.stumpel@mumc.nl.
Maastricht University Medical Centre · NLRadboud University Nijmegen · NLSwedish University of Agricultural Sciences · SEUniversity of Sussex · GBAmsterdam UMC Location Vrije Universiteit Amsterdam · NLNational Institutes of Health · USNational Research Centre · EG

Funding

Medical Research Council MR/T012978/1
6 · The paper itself

Abstract

Nucleotide metabolism is a complex pathway regulating crucial cellular processes such as nucleic acid synthesis, DNA repair and proliferation. This study shows that impairment of the biosynthesis of one of the building blocks of DNA, dTTP, causes a severe, early-onset neurodegenerative disease. Here, we describe two unrelated children with bi-allelic variants in DTYMK, encoding dTMPK, which catalyzes the penultimate step in dTTP biosynthesis. The affected children show severe microcephaly and growth retardation with minimal neurodevelopment. Brain imaging revealed severe cerebral atrophy and disappearance of the basal ganglia. In cells of affected individuals, dTMPK enzyme activity was minimal, along with impaired DNA replication. In addition, we generated dtymk mutant zebrafish that replicate this phenotype of microcephaly, neuronal cell death and early lethality. An increase of ribonucleotide incorporation in the genome as well as impaired responses to DNA damage were observed in dtymk mutant zebrafish, providing novel pathophysiological insights. It is highly remarkable that this deficiency is viable as an essential component for DNA cannot be generated, since the metabolic pathway for dTTP synthesis is completely blocked. In summary, by combining genetic and biochemical approaches in multiple models we identified loss-of-function of DTYMK as the cause of a severe postnatal neurodegenerative disease and highlight the essential nature of dTTP synthesis in the maintenance of genome stability and neuronal survival.

Indexed as

AnimalsFemaleHumansMaleMicrocephalyMutationNeurodegenerative DiseasesNucleoside-Phosphate KinaseZebrafishdTMP kinaseNucleoside-Phosphate KinasedTMPKDTYMKGenome instabilityNucleotide metabolismZebrafish

Identifiers

PMID34918187
PMCPMC8742820
OpenAlexW4200138245

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.